NCT03133351 is a clinical trial of PCM in Coagulation, sponsored by Entegrion, Inc..

Who is sponsoring NCT03133351?

NCT03133351 is sponsored by Entegrion, Inc..

What drugs are being tested in NCT03133351?

Interventions in NCT03133351: PCM.

What condition does NCT03133351 study?

NCT03133351 studies Coagulation.

Is NCT03133351 still recruiting?

NCT03133351 is currently status unknown. Last updated 16 April 2020.

Last reviewed 2020-04-16 · How we verify

NCT03133351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers

Status unknown Last updated 16 April 2020

What this trial tests

trial testing PCM in Coagulation in 240 participants. Status unknown.

Timeline

4 April 2017

Primary endpoint
30 December 2020

31 March 2021

Quick facts

Lead sponsor	Entegrion, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	240
Start date	4 April 2017
Primary completion	30 December 2020
Estimated completion	31 March 2021
Sites	2 locations across United States

Drugs / interventions tested

Conditions studied

Coagulation — all drugs for Coagulation →

Sponsor

Entegrion, Inc. — full company profile →

Who can join

18 and older, any sex, with Coagulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is intended to define the PCM normal laboratory range.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coagulation

Currently open trials in the same condition.

NCT07014722 — Contact Activation of Coagulation in Newly Inserted Central Venous Catheters · NA · recruiting
NCT07012291 — Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™ · recruiting
NCT06513611 — Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome · recruiting
NCT05865691 — Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease · recruiting
NCT05853796 — Observational Dutch Young Symptomatic StrokE studY - nEXT · recruiting

Other Entegrion, Inc. trials

Trials by the same sponsor.

NCT03700723 — Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy · Phase 2 · terminated
NCT03679286 — Comparative Analysis of PCM With ROTEM in the Measurement of Viscoelastic Coagulation Parameters · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03133351 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Entegrion, Inc.
Last refreshed: 16 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03133351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing